Palvella Therapeutics (PVLA) Cash from Financing Activities (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Cash from Financing Activities for 14 consecutive years, with $214.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 17964.48% year-over-year to $214.7 million; the TTM figure through Mar 2026 stood at $215.3 million (up 150.65% YoY), while the FY2025 annual figure was -$660000.0, down 100.76% from the prior year.
• Cash from Financing Activities grew to $214.7 million in Q1 2026 per PVLA's latest filing, from -$49000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $214.7 million in Q1 2026 and bottomed at -$14.8 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $22.4 million across 5 years, with a median of $315500.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 15993.55% — and 2026, when it soared 17964.48%.
• Palvella Therapeutics' Cash from Financing Activities stood at $93000.0 in 2022, then tumbled by 15993.55% to -$14.8 million in 2023, then jumped by 605.95% to $74.8 million in 2024, then tumbled by 100.07% to -$49000.0 in 2025, then soared by 438326.53% to $214.7 million in 2026.
• Business Quant data shows PVLA's Cash from Financing Activities at $214.7 million in Q1 2026, -$49000.0 in Q4 2025, and $242000.0 in Q3 2025.